Rozzano

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia3 trials
• Colorectal cancer3 trials
• Myelodysplastic syndromes3 trials
• Acute myeloid leukaemia2 trials
• Coronary artery disease2 trials
• Lung cancer2 trials
• Prostate cancer2 trials
• Stroke2 trials
• Childhood cancers1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Diffuse large B-cell lymphoma1 trial
• Familial hypercholesterolaemia1 trial
• and 9 more

Phase

• Phase 17 trials
• Phase 36 trials
• Phase 23 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Terminated7 trials
• Completed5 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals21 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

  NCT07543419· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

  NCT07093801· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 2 Study of Rapcabtagene Autoleucel in Myositis

  NCT06665256· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

  NCT05838768· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

  NCT05552469· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

  NCT04857372· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hidradenitis suppurativa1 recruiting

Closed trials

• Terminated

  Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

  NCT04952753· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

  NCT04838626· Phase 2/3· Novartis Pharmaceuticals· Source

• Terminated

  VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

  NCT04702425· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

  NCT04727723· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

  NCT03798626· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

  NCT03439046· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

  NCT02974725· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

  NCT02900651· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

  NCT01828099· Phase 3· Novartis Pharmaceuticals· Source